Saturday 17 October 2026 Export MDCX’s income statement to Excel — free account

Medicus Pharma Ltd

MDCX Healthcare Drug Manufacturers General

In the quarter to June 2026, EPS grew 51.2% and free cash flow fell 27.7%, each against the same quarter a year earlier.

3.27 0.16 −4.66%

Follow MDCX

Alert me

Market cap: $6.3M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 78.53%

Capital & Financial Ratios $m

Market Cap 6.34

Revenue —

Net Income (44.89)

Free Cash Flow (29.32)

Net Debt 2.81

Current Ratio 1.57

Debt/Equity (10.42)

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 75.55%

Next Y EPS Growth 45.15%

Next Y revenue growth —

Next 5Y EPS Growth 50.12%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	2	4	9	15
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	2	5	10	17

	2023	2024	2025	Q'26
Payables	0	1	3	7
ST’ Debt	—	—	—	—
Other	—	—	—	—
	1	2	10	11

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	—	0.00%
Earnings	—	—	0.00%
Book Value	—	—	0.00%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(7)	—	—	—
’25	(4)	(5)	(7)	(7)	(23)
’24	(1)	(3)	(3)	(3)	(10)
’23	0	0	0	(3)	(4)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(7)	—	—	—
’25	(4)	(5)	(7)	(7)	(23)
’24	(1)	(3)	(3)	(3)	(10)
’23	0	0	0	(3)	(4)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.31)	(0.21)	—	—	—
’25	(0.42)	(0.43)	(1.12)	(0.82)	(2.74)
’24	(0.21)	(0.44)	(0.24)	(0.18)	(1.16)
’23	(0.13)	(0.13)	(1.47)	0.20	(1.53)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	—	—	90.00	72.50	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	—	—	161.50	447.00
People
People	Employees	—	—	—	—	—	—	—	5	12	16
	Revenue/emp, $m	—	—	—	—	—	—	—	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	—	—	—	—	—	—	—
	EBT	—	—	—	—	—	—	(2)	(5)	(11)	(35)
	EBT margin, %	—	—	—	—	—	—	0.00	0.00	0.00	0.00
	Net income	—	—	—	—	—	—	(2)	(5)	(11)	(35)
	Depreciation	—	—	—	—	—	—	—	—	—	—
Per share, $
Per share, $	Revenue	—	—	—	—	—	—	0.00	0.00	0.00	0.00
	Earnings	—	—	—	—	—	—	(0.45)	(1.53)	(1.16)	(2.74)
	Cash flow	—	—	—	—	—	—	(0.28)	(1.20)	(1.07)	(1.32)
	Capex	—	—	—	—	—	—	0.00	0.00	0.00	0.00
	Free cash flow	—	—	—	—	—	—	(0.28)	(1.20)	(1.07)	(1.32)
	Book value	—	—	—	—	—	—	(3.24)	0.32	0.33	0.00
	Shares, m	—	—	—	—	—	—	4	3	10	17
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	—	—	(1)	(4)	(10)	(23)
	Capex	—	—	—	—	—	—	—	—	—	—
	Free cash flow	—	—	—	—	—	—	(1)	(4)	(10)	(23)
Balance, $m
Balance, $m	Working capital	—	—	—	—	—	—	(12)	1	3	0
	Total debt	—	—	—	—	—	—	—	—	—	—
	Net debt	—	—	—	—	—	—	0	(2)	(4)	(9)
	Shareholders’ equity	—	—	—	—	—	—	(12)	1	3	0
Returns, %
Returns, %	ROA	—	—	—	—	—	—	0.00	(488.54)	(295.90)	(602.13)
	ROIC	—	—	—	—	—	—	0.00	0.00	0.00	0.00
	ROE	—	—	—	—	—	—	0.00	95.88	(525.45)	(2,981.87)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SNY Sanofi	$96.0B	21.3×	—	+17.35% (above 0%: growing)	−90.76% (below 0%: shrinking)	−45.06% (below 0%: shrinking)	75.47%	17.48%	Compare
BIIB Biogen Inc.	$34.8B	41.0×	31.5×	+3.42% (above 0%: growing)	−84.76% (below 0%: shrinking)	+103.28% (above 0%: growing)	71.60%	5.52%	Compare
OGN Organon & Co.	$3.6B	17.4×	5.2×	−2.26% (below 0%: shrinking)	−26.79% (below 0%: shrinking)	−82.97% (below 0%: shrinking)	54.36%	20.67%	Compare
GRFS Grifols, S.A.	$2.0B	8.5×	—	+5.76% (above 0%: growing)	+466.92% (above 0%: growing)	+300.52% (above 0%: growing)	36.47%	14.76%	Compare
AMRN Amarin Corporation PLC	$244.4M	— (loss-making)	— (loss-making)	−41.97% (below 0%: shrinking)	n/m	−60.23% (below 0%: shrinking)	35.51%	(28.45%)	Compare
NSRX Nasus Pharma Ltd.	$37.1M	—	—	—	—	−486.98% (below 0%: shrinking)	—	—	Compare
MIRA MIRA Pharmaceuticals, Inc.	$27.7M	— (loss-making)	—	—	n/m	−50.76% (below 0%: shrinking)	—	0.00%	Compare
SCLX Scilex Holding Company	$19.8M	— (loss-making)	— (loss-making)	−22.78% (below 0%: shrinking)	n/m	−203.76% (below 0%: shrinking)	51.88%	(385.02%)	Compare
MDCX Medicus Pharma Ltd	$6.3M	— (loss-making)	—	—	n/m	−27.70% (below 0%: shrinking)	—	0.00%
Median of peers	$1.1B	19.3×	—	+0.58%	−55.77%	−55.49%	53.12%	5.52%

All 21 Drug Manufacturers General stocks →

Medicus Pharma Ltd (MDCX) key facts

Medicus Pharma Ltd (MDCX) is a Drug Manufacturers General company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, MDCX traded at $3.27, a market capitalization of $6.3 million.
Return on equity was −2,981.9% and debt-to-equity -10.42.

Source: company filings (standardised) and stockrow calculations.